Superior oblique myokymia: efficacy of medical treatment.
Détails
ID Serval
serval:BIB_C69A53B5231E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Superior oblique myokymia: efficacy of medical treatment.
Périodique
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus / American Association for Pediatric Ophthalmology and Strabismus
ISSN
1091-8531
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
11
Numéro
3
Pages
254-7
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
PURPOSE: Superior oblique myokymia (SOM) is an uncommon disorder characterized by episodic monocular oscillopsia. Several medications have been reported to be of benefit for some patients with this condition, but the efficacy of medical treatment has not been well established and little long-term follow-up data are available. The purpose of this study was to better clarify the role of medical therapy in the management of SOM. METHODS: A retrospective review of patients with this disorder seen in an outpatient neuro-ophthalmology clinic. The diagnosis of SOM was based on a history of episodic unilateral oscillopsia with or without torsional diplopia. Twenty-seven patients with SOM were identified. Twenty of these were treated medically and these formed the basis of the study. Follow-up interval ranged from 1 to 12.5 years (mean, 6.5 years). The main outcome measure was relief of oscillopsia. RESULTS: Fifteen of the 18 patients treated with carbamazepine (83%) reported some benefit, 6 of whom continue to do well on medication 9 months to 5 years later. In four patients improvement was only transient and in five others treatment was subsequently discontinued for various reasons. In addition, one patient had sustained benefit from phenytoin, one from propranolol, and one from propranolol plus valproic acid. We found no treatment success with baclofen. Overall, nine patients (45%) enjoy sustained benefit unassociated with adverse side effects. CONCLUSIONS: In contrast to previous reports emphasizing the efficacy of surgery for SOM, our data demonstrate the potential benefits of medical treatment for patients with this disorder.
Mots-clé
Adolescent, Adult, Aged, Anticonvulsants/therapeutic use, Carbamazepine/therapeutic use, Diplopia/drug therapy, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Optical Illusions/drug effects, Phenytoin/therapeutic use, Propranolol/therapeutic use, Retrospective Studies, Treatment Outcome, Trochlear Nerve Diseases/drug therapy, Valproic Acid/therapeutic use
Pubmed
Web of science
Création de la notice
17/11/2009 14:39
Dernière modification de la notice
20/08/2019 15:42